Finally, we do not draw conclusions regarding the role of the EPH/ephrin system in the mutational profile of pediatric neoplastic subtypes, as the exact percentages of mutations in EPH/ephrin members across the age spectrum of pediatric and adulthood populations with neoplastic disease have not been established yet and is a potential field for further research via large genomic analyses. This evidence concerns the gene EPHA1 and neoplasm.